China’s market regulator fines **Tiansheng Pharmaceutical Group** and its controlling shareholder for violations. The penalties follow an investigation into irregularities in the company’s financial disclosures and shareholder transactions. Authorities cite failures to comply with disclosure rules and internal governance standards.
Chongqing Pharmaceutical CO., LTD. acquires a 51% stake in Chongqing Changsheng Medicine Co., Ltd. from Tiansheng Pharmaceutical Group Co., Ltd. The transaction expands Chongqing Pharmaceutical’s presence in the pharmaceutical distribution sector. The deal aligns with Chongqing Pharmaceutical’s growth strategy in China’s medicine supply chain.
Tiansheng Pharmaceutical Group Co Ltd’s controlling shareholder receives a 19-year prison sentence for bribery. The ruling follows a legal case involving alleged corruption tied to the pharmaceutical company’s operations. Authorities confirm the conviction as part of ongoing investigations into financial misconduct.
Tiansheng Pharmaceutical Group Co Ltd places its chairman under surveillance over alleged embezzlement. The company, a pharmaceutical manufacturer, faces regulatory scrutiny amid the investigation. Authorities examine financial irregularities tied to the chairman’s actions, though no formal charges have been filed.
